Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Extensive research

Story’s next chapter begins

By Mikael RautanenCEO
Revenio Group
Download report (PDF)

Revenio’s investor story remains interesting, as the strategy’s next phase begins after the acquisition of CenterVue. The core business continues to grow very profitably, the underlying market has strong structural growth drivers, and the products have exceptionally strong competitive advantages. Revenio has also shown over the years how capable they are in value creation through investments into product development, structural transitions, and long-term growth development projects.

Login required

This content is only available for logged in users

Create account

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures01.10.2019

201819e20e
Revenue30.750.167.0
growth-%14.6 %63.4 %33.8 %
EBIT (adj.)10.214.321.2
EBIT-% (adj.)33.3 %28.5 %31.6 %
EPS (adj.)0.340.470.63
Dividend0.280.340.44
Dividend %2.2 %1.6 %2.0 %
P/E (adj.)36.945.934.6
EV/EBITDA27.149.425.9

Forum discussions

Revenio’s trading volume today, with a rising share price, is many times higher than normal. Those in the know, know, I don’t…
11/25/2025, 7:50 PM
by Sissos
16
The costs of disposable instruments were investigated in a US study, including those for rebound tonometry probes. The data is based on a clinic...
11/10/2025, 11:07 AM
by veronmaksaja
5
op-media.fi – 14 Oct 25 Osakkeiden top 10 – Nämä ovat ammattilaisten valinnat pitkän aikavälin... Asiantuntijat listasivat kotimaiset yhtiöt...
11/9/2025, 3:13 PM
by Sissos
12
In past quarters, there have been one-off costs which, reading between the lines, have been related to potential acquisitions. One would gradually...
11/9/2025, 7:59 AM
by Temew
10
More precious than gold? Revenio’s stock is highly valued. DCF shows 28€ if operating profit doubles in 5 years.
10/31/2025, 10:33 AM
by LeFevre
15
And @Juha_Kinnunen’s updated view, there’s still excitement for the rest of the year: Revenio Q3'25: Q4 ratkaisee tämänkin vuoden - Inderes ...
10/31/2025, 7:30 AM
by NukkeNukuttaja
13
Updated view.
10/31/2025, 7:24 AM
by KuHa
11
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.